Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel

Sopheon Terug naar discussie overzicht

PB 8 juni 2017

11 Posts
| Omlaag ↓
  1. [verwijderd] 8 juni 2017 08:19
    AGM Statement

    At today’s Annual General Meeting of Sopheon, the international provider of software and services that help organizations generate more revenues and profits from new products, the Board will give shareholders an update and review of the business.

    It gives us great pleasure to report another year of excellent financial and operational progress, as we continue to advance our strategy of being the world’s leading solution provider of enterprise-class innovation management software solutions. A year ago we were pleased to report solid strategic and financial progress, and we are delighted to say the same applies today, one year later. Last year we grew revenues to $23.2m from $20.9m in 2015 and $18.3m in 2014, and we delivered another substantial increase in profitability, with EBITDA rising to $5.2m before exchange gains ($5.6m including exchange gains) from $4.1m the year before, which was itself more than triple the 2014 performance. Profit before tax rose to $3.0m from $1.2m in 2015. In 2016 we also initiated partial recognition of our substantial deferred tax asset, which resulted in a profit after tax of $4.3m. Net assets nearly doubled to $10.4m from $5.5m in 2015.

    The revenue growth was underpinned by a rise to 49 license transactions from 42 the year before, of which 17 were new customers, up from 14 in 2015. We continued to invest in and show traction with the two elements of our go-to-market strategy – both the global end-to-end enterprise solution, and the “out-of-the-box” Accolade Express solution for quicker time to value. Our market strength in the consumer products industry was again recognized, with Sopheon being voted a “top ten software vendor” for the seventh consecutive year by the CGT magazine readership. In addition to this progress, we also saw strong traction in the aerospace and defense and chemicals sectors. Sopheon’s commercial success is being achieved in parallel with strategic and operational initiatives aimed at underpinning our continued growth for the next three to five years. We maintained our rapid pace of product development releases, with another three in 2016, further advancing our platform for enterprise utilization and flexibility, followed by version 11.1 which we released in February this year.

    This continued investment supports our growth strategy in two areas. One is to capitalize on existing client demand to expand their Accolade investment beyond product innovation to support Enterprise Initiative Management tracking and decision making. This market opportunity has been validated by Gartner’s 2016 Market Guide for Strategy Execution Software and their recognition of Sopheon in this emerging space. We are also delighted to announce Sopheon’s inclusion in Gartner’s Magic Quadrant for Project Portfolio Management, just last week. Sopheon is the only vendor referenced in both the Market Guide for Strategy Execution Software and the Magic Quadrant for Project Portfolio Management. In Sopheon’s view, this provides strong validation of our unique position and strength in the enterprise portfolio management, enterprise initiative management, and product development markets. The second growth area we continue to invest in is our vertical industry focus on chemical, consumer goods, food and beverage, aerospace and defense, and high-tech. In addition, we are researching the insurance, service and automobile industries as we have recently signed customers in these areas. Such customers help us to understand the value proposition Accolade can bring to new vertical markets, and to determine if these represent further new growth opportunities for the Company.

    Following several years of clarifying our debt, equity and listing structure, our corporate activity has been relatively quiet in the past year, other than extension of the maturity of our debt facilities to January 2019.

    Sopheon has a market-leading solution, global reach, solid financials, a clear corporate structure, an accelerating market, and most importantly great people – a real platform for growth. Full year revenue visibility for 2017 from contracted business and recurring revenue streams is now at $17.5m, compared to just under $17.0m at this time last year. This includes 20 license orders, up from 14 for the same period last year. This is a different mix compared to this time last year, which included a very substantial order from an existing enterprise tier customer. This is further evidence of the increased adoption of the Company’s software and services from a broader range of businesses, including several with expected upside revenue later this year. Sopheon also continues its focus on working with and growing relationships with global admired blue chip customers such as Electrolux, PepsiCo, Proctor & Gamble and Merck. These factors, together with a strong sales pipeline, give the Board confidence in meeting our strategic and financial plans for the year, and in delivering continued positive development in our performance for 2017 and beyond.
  2. forum rang 4 Diegy 8 juni 2017 09:08
    Cijfers zijn niet super. Zie de koers zo wel naar rood gaan. Zoals ik gister al zei koers is in 1 jaar tijd met 400% gestegen. Ik had veel meer van de cijfers verwacht wat zo een mega stijging rechtvaardigd.
  3. [verwijderd] 8 juni 2017 10:34
    Cijfers zijn prima (niet 'super' nee). Weer beter dan vorig jaar en toen is in het tweede kwartaal zelfs een hele grote order afgesloten. In 2,5 maand tijd is er $3M omzet bijgekomen. Zou dat zo doorzetten dan komt de jaaromzet op $24,7M. De huidige koers is al substantieel te laag t.o.v. de cijfers van vorig jaar - k/w van slechts 8 - en zo lang het bedrijf doorgroeit wordt het opwaarts potentieel alleen maar groter.
  4. [verwijderd] 8 juni 2017 10:57
    quote:

    VeniVidiMerui schreef op 8 juni 2017 10:34:

    Cijfers zijn prima (niet 'super' nee). Weer beter dan vorig jaar en toen is in het tweede kwartaal zelfs een hele grote order afgesloten. In 2,5 maand tijd is er $3M omzet bijgekomen. Zou dat zo doorzetten dan komt de jaaromzet op $24,7M. De huidige koers is al substantieel te laag t.o.v. de cijfers van vorig jaar - k/w van slechts 8 - en zo lang het bedrijf doorgroeit wordt het opwaarts potentieel alleen maar groter.
    een doorgroei de komende 5 jaar + een sterke verkoop pipelijn, finn cap geeft een koersdoel van 620 pence.
  5. [verwijderd] 8 juni 2017 17:47
    Sopheon Plc 64.2% Potential Upside Indicated by finnCap
    Posted by: Amilia Stone 8th June 2017

    Sopheon Plc with EPIC/TICKER (LON:SPE) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘CORPORATE’ this morning by analysts at finnCap. Sopheon Plc are listed in the Technology sector within AIM. finnCap have set their target price at 620 GBX on its stock. This indicates the analyst now believes there is a potential upside of 64.2% from the opening price of 377.5 GBX. Over the last 30 and 90 trading days the company share price has decreased 17.5 points and decreased 105.9 points respectively. The 1 year high share price is 513.9 GBX while the year low share price is currently 88.5 GBX.
    Sopheon Plc has a 50 day moving average of 424.39 GBX and a 200 day moving average of 376.66. There are currently 7,423,512 shares in issue with the average daily volume traded being 46,840. Market capitalisation for LON:SPE is £26,873,113 GBP.
  6. [verwijderd] 11 juni 2017 11:59
    AGM Statement

    Even wat punten benoemen na het PB van jongstleden donderdag.

    Heb ze niet allemaal benoemd, want mijn Engels is geen 100%.

    Mocht ik er fouten in hebben staan, dan hoor ik het graag, of als ik iets belangrijks ben vergeten, idem.

    Wederom een jaar met uitstekende financiële en operationele vooruitgang.

    Inkomsten 2015 20.9 naar 23.2 in 2016. + 11 procent.

    Winst in 2016 ( na afdracht belastingen enzovoorts ) 4.3 miljoen

    Netto activa van 5.5 naar 10.4. + 90%.

    License van 42 naar 49. + 17%.

    Wederom erkend door CGT magazine voor het zevende opeenvolgende jaar.

    Sterke tractie in de sectoren lucht en defensie en chemicaliën.

    Het commerciële succes van Sopheon wordt ook bereikt met strategische en operationele initiatieven die de verdere groei de komende 3 tot 5 jaar ondersteunen.

    Groei strategie op 2 gebieden, onder andere bij bestaande klanten om hun Accolade investering verder te verbreden.

    Schuld faciliteiten tot en met januari 2019.

    Visible nu 17.5 tegenover 17.0. + 3%. Wel toename, maar niet echt spectaculair.

    20 licence orders tegenover 14 vorig jaar. + 43%

    Verder toegenomen bewijs van goedkeuring voor wat betreft de software en diensten van Sopheon, vanuit een scala van bedrijven, waarvan van een aantal wordt verwacht dat ze aan omzet gaan bijdragen later dit jaar.

    Sterke verkoop pijplijn.

    Kortom, vrij goed. 24 augustus halfjaar cijfers.
11 Posts
|Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.846
AB InBev 2 5.296
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.580 46.613
ABO-Group 1 19
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 253
Accsys Technologies 22 9.008
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 160
ADMA Biologics 1 32
Adomos 1 126
AdUX 2 457
Adyen 13 16.561
Aedifica 2 832
Aegon 3.257 320.196
AFC Ajax 537 7.025
Affimed NV 2 5.769
ageas 5.843 109.781
Agfa-Gevaert 13 1.881
Ahold 3.536 74.004
Air France - KLM 1.024 34.373
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.778
Alfen 12 16.711
Allfunds Group 3 1.224
Almunda Professionals (vh Novisource) 651 4.247
Alpha Pro Tech 1 17
Alphabet Inc. 1 339
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.485 114.769
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.821 240.424
AMG 965 126.340
AMS 3 73
Amsterdam Commodities 303 6.524
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 382
Antonov 22.632 153.605
Aperam 91 14.177
Apollo Alternative Assets 1 17
Apple 5 322
Arcadis 251 8.627
Arcelor Mittal 2.024 318.730
Archos 1 1
Arcona Property Fund 1 267
arGEN-X 15 9.162
Aroundtown SA 1 183
Arrowhead Research 5 9.295
Ascencio 1 20
ASIT biotech 2 697
ASMI 4.107 37.736
ASML 1.762 77.311
ASR Nederland 18 4.160
ATAI Life Sciences 1 7
Atenor Group 1 333
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.701
Axsome Therapeutics 1 177
Azelis Group 1 49
Azerion 7 2.681

Beleggingsideeën van onze partners

Macro & Bedrijfsagenda

  1. 14 mei

    1. B&S Group Q1-cijfers
    2. OCI Q1-cijfers
    3. Bayer Q1-cijfers
    4. Agfa-Gevaert Q1-cijfers
    5. Dui inflatie april (def)
    6. VK werkloosheid maart
    7. Dui ZEW-index economisch sentiment mei
    8. VS ondernemersvertrouwen MKB april
    9. Home Depot Q1-cijfers
    10. Maandrapport OPEC
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht